Skip to main content
SpringerLink
Log in

Polypharmazie in der Behandlung von Menschen mit geistiger Behinderung

  • Chapter
Polypharmazie in der Behandlung psychischer Erkrankungen

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

6. Literatur

  1. AACAP (1999) Practice parameters for the assessment and treatment for children, adolescents, and adults with mental retardation and comorbid mental disorders. J Am Acad Child Adolesc Psychiatry 38[Suppl] 12: 5–31

    Google Scholar 

  2. Advokat CD, Mayville EA, Matson JL (2000) Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Res Dev Disabil 21: 75–84

    Article  PubMed  CAS  Google Scholar 

  3. Airaksinen EM, Matilainen R, Mononen T, Mustonen K, Partanen J, Jokela V (2000) A population-based study on epilepsy in mentally retarded children. Epilepsia 41: 1214–1220

    Article  PubMed  CAS  Google Scholar 

  4. Aman MG (1983) Psychoactive drugs in mental retardation. In: Matson JL, Andrasik F (eds) Treatment issues and innovations in mental retardation. Plenum Press, New York, p 455–513

    Google Scholar 

  5. Aman MG, Singh NN (1988) Patterns of drug use: Methodological considerations, measurement techniques, and future trends. In: Aman MG, Singh NN (eds) Psychopharmacology of the developmental disabilities. Springer, Berlin Heidelberg New York Tokyo, p 1–28

    Google Scholar 

  6. Ballinger BR, Ballinger CB, Reid AH, McQueen E (1991) The psychiatric symptoms, diagnoses and care need of 100 mentally handicapped patients. Br J Psychiatry 158: 251–254

    Article  PubMed  CAS  Google Scholar 

  7. Branford D (1994) A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. J Intellect Dis Res 38: 577–586

    Article  Google Scholar 

  8. Baumeister AA, Todd ME, Sevin JA (1993) Efficacy and specifity of pharmacological therapies for behavioral disorders in persons with mental retardation. Clin Neuropharmacol 16: 271–294

    PubMed  CAS  Google Scholar 

  9. Cosgrove PVF (1996) Risperidone added to methylphenidate in attention deficit hyperactivity disorder. Eur Neuropsychopharmacol 6[Suppl] 3: 11–12

    Article  Google Scholar 

  10. Davanzo PA, Belin TR, Widawski MH, King BH (1998) Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard 102: 427–437

    Article  PubMed  CAS  Google Scholar 

  11. Deb S, Thomas M, Bright C (2001) mental disorder in adults with intellectual disability. 2: The rate of behaviour disorders among a community-based population aged between 16 and 64 years. J Intellect Dis Res 45: 506–514

    Article  CAS  Google Scholar 

  12. Dekker MC, Koot HM (2003) DSM-IV disorders in children with borderline to moderate intellectual disability. I: prevalence and impact. J Am Acad Child Adolesc Psychiatry 42: 915–922

    Article  PubMed  Google Scholar 

  13. DSM-IV-TR (2003) Diagnostisches und Statistisches Manual Psychischer Störungen. Hogrefe, Göttingen

    Google Scholar 

  14. Emerson E (2003) Prevalence pf psychiatric disorders in children and adolescents with and without intellectual disability. J Intellect Dis Res 47: 51–58

    Article  CAS  Google Scholar 

  15. Espie CA, Watkins J, Curtice L, Espie A, Duncan R, Ryan JA (2003) Psychopathology in people with epilepsy and intellectual disability; an investigation of potential explanatory variables. J Neurol neurosurg Psychiatry 74: 1485–1492

    Article  PubMed  CAS  Google Scholar 

  16. Gadow KD (1986) Children on medication. College Hill Press, San Diego

    Google Scholar 

  17. Gaedt C (1995) Psychopharmakotherapie bei Menschen mit geistiger Behinderung. In: Dosen A (Hrsg.) Psychische Erkrankungen und psychische Störungen bei Menschen mit geistiger Behinderung. Gustav Fischer, Stuttgart

    Google Scholar 

  18. Härtter S (2004) Moderne Antidepressiva: Pharmakokinetik, Interaktionspotenzial und TDM. Pharm Unserer Zeit 33: 296–303

    Article  PubMed  Google Scholar 

  19. Häßler F (1998) Psychopharmakatherapie bei geistig Behinderten. Psychopharmakotherapie 5: 76–80

    Google Scholar 

  20. Häßler F, Buchmann J (2004) Die Wirksamkeit der Rivastigmin-Therapie zur Behandlung einer Demenz bei Menschen mit geistiger Behinderung — drei Kasuistiken. Akt Neurologie 31: 52

    Google Scholar 

  21. Häßler F, Schläfke D (2004) Impulskontrollstörungen und ihre medikamentöse Behandlung bei Sexualstraftätern. Recht&Psychiatrie 22: 213–218

    Google Scholar 

  22. Häßler F, Tilch P, Buchmann J (2004) Psychopharmakatherapie und andere therapeutische Konzepte in der Behandlung von Menschen mit geistiger Behinderung. In: Häßler F, Fegert JM (Hrsg) Geistige Behinderung und seelische Gesundheit. Schattauer, Stuttgart, S 123–165

    Google Scholar 

  23. Hertzman M (2003) Galantamin in the treatment of adult autism: a report of three clinical cases. Intl J Psychiatry Med 33: 395–398

    Article  Google Scholar 

  24. Huber B (2004) Epilepsien bei geistiger Behinderung. In: Häßler F, Fegert JM (Hrsg) Geistige Behinderung und seelische Gesundheit. Schattauer, Stuttgart, S 193–251

    Google Scholar 

  25. ICD-10 (2000) Internationale Klassifikation psychischer Störungen. Hans Huber, Göttingen

    Google Scholar 

  26. ICF (2001) www.dimdi.de

    Google Scholar 

  27. King BH (2002) Psychopharmacology in mental retardation. Curr Opin Psychiatry 15: 497–502

    Article  Google Scholar 

  28. Lewis JN, Tonge BJ, Mowat DR, Einfeld SL, Siddons HM, Rees VW (2000) Epilepsy and associated psychopathology in young people with intellectual disability. J Paediatr Child Health 36: 172–175

    Article  PubMed  CAS  Google Scholar 

  29. Lott IT, McGregor M, Engelman L, Touchette P, Tournay A, Sandman C, Fernandez G, Plon L, Walsh D (2004) Longitudinal prescribing patterns for psychoactive medications in community-based individuals with developmental disabilities: utilization of pharmacy records. J Intellect Dis Res 48: 563–571

    Article  CAS  Google Scholar 

  30. Masi G, Cosenza A, Mucci M, Brovedani P (2001) Open trial risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40: 1206–1214

    Article  PubMed  CAS  Google Scholar 

  31. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK (2000) Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trail. Int J Geriat Psychiatry 15: 387–392

    Article  CAS  Google Scholar 

  32. Meins W, Auwetter J, Krausz M, Turnier Y (1993) Behandlung mit Psychopharmaka in unterschiedlichen Einrichtungen für geistig Behinderte. Nervenarzt 64: 451–455

    PubMed  CAS  Google Scholar 

  33. Müller U, Wolf H, Kiefer M, Gertz HJ (2003) Nationale und internationale Demenz-Leitlinien im Vergleich. Fortschr Neurol Psychiat 71: 285–295

    Article  PubMed  Google Scholar 

  34. Pearson DA, Lane DM, Santos CW, Casat CD, Jerger SW, Loveland KA, Faria LP; Mansour R, Henderson JA, Payne CD, Roache JD, Lachar D, Cleveland LA (2004) Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response. J Am Acad Child Adolesc Psychiatry 43: 686–698

    Article  PubMed  Google Scholar 

  35. Roeleveld N, Zielhuis GA, Gabreels F (1997) The prevalence of mental retardation: a critical review of recent literature. Dev Med Child Neurol 39: 125–139

    Article  PubMed  CAS  Google Scholar 

  36. Rösler M, Retz-Junginger P, Retz W (1998) Alzheimer Demenz und Exelon®. Thieme, Stuttgart

    Google Scholar 

  37. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Szählin HB, Hartman R, Gharabawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 318: 633–640

    PubMed  Google Scholar 

  38. Santosh PJ, Baird G (1999) Psychopharmacotherapy in children and adults with intellectual disability. Lancet 354: 233–242

    Article  PubMed  CAS  Google Scholar 

  39. Singh NN, Ellis CR, Wechsler HBA (1997) Psychopharmacoepidemiology of mental retardation: 1966 to 1995. J Child Adolesc Psychopharmacol 4: 255–266

    Article  Google Scholar 

  40. Sperling W, Demling J (1997) Neue Antidepressiva. Arzneimitteltherapie 15: 74–83

    Google Scholar 

  41. Spreat S, Conroy J, Jones J (1997) Use of psychotropic medication in Oklahoma: a statewide survey. Am J Ment Retard 102: 80–85

    Article  PubMed  CAS  Google Scholar 

  42. Spreat S, Conroy JW, Fullerton A (2004) Statewide longitudinal survey of psychotropic medication use for persons with mental retardation: 1994 to 2000. Am J Ment Retard 109: 322–331

    Article  PubMed  Google Scholar 

  43. Steinhausen HC (2003) Allgemeine und spezielle Psychopathologie. In: Neuhäuser G, Steinhausen HC (Hrsg) Geistige Behinderung. Kohlhammer, Stuttgart, S 71–80

    Google Scholar 

  44. Stolker JJ, Koedoot PJ, heerdink ER, Leufkens HGM, Nolen WA (2002) Psychotropic drug use in intellectually disabled group-home residents with behavioural problems. Pharmacopsychiatry 35: 19–23

    Article  PubMed  CAS  Google Scholar 

  45. Tiedtke K, Haury S, Eichhorn C, Nordbeck R, Fegert JM, Häßler F (2002) Einsatz einer kombinierten Psychopharmakotherapie mit Risperidon und Methylphenidat bei Kindern, die eine expansive Verhaltensstörung und eine leichte Intelligenzminderung aufweisen. In: Lehmkuhl U (Hrsg) Seelische Krankheit im Kindes-und Jugendalter — Wege zur Heilung. Vandenhoeck&Ruprecht, Göttingen, S 130–131

    Google Scholar 

  46. Verhoeven WMA, Veendrik-Meekens, Jacobs GAJ, van den Berg YWMM, Tuinier S (2001) Citalopram in mentally retarded patients with depression: a long-term clinical investigation. Eur Psychiatry 16: 104–108

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Kinder- und Jugendneuropsychiatrie, Psychotherapie, Universität Rostock, Gehlsheimer Str. 20, 18147, Rostock

    Prof. Dr. med. Frank Hässler

Authors
  1. Prof. Dr. med. Frank Hässler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag/Wien

About this chapter

Cite this chapter

Hässler, F. (2006). Polypharmazie in der Behandlung von Menschen mit geistiger Behinderung. In: Polypharmazie in der Behandlung psychischer Erkrankungen. Springer, Vienna. https://doi.org/10.1007/3-211-31221-8_4

Download citation

  • DOI: https://doi.org/10.1007/3-211-31221-8_4

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-25286-4

  • Online ISBN: 978-3-211-31221-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation